For the Inventor, By the Inventor

Enter inventor name

San Jose, CA, United States of America

Ryan Hudson

USPTO Granted Patents = 41 (Patent Applications = 1)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 9)

Average Co-Inventor Count = 4.5

ph-index = 8

Forward Citations = 236(Granted Patents)

Location History:

Sunnyvale, CA (US) (2010 - 2014)
San Mateo, CA (US) (2022 - 2023)
San Jose, CA (US) (2011 - 2024)

Company Filing History:

Theravance Biopharma R&d Ip, LLC

Theravance, Inc.

Corvus Pharmaceuticals, Inc.

Angel Pharmaceutical Co., Ltd.

Years Active: 2010-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

JAK Kinase Inhibitors

Pyrimidine Compounds

Bruton's Tyrosine Kinase

Neprilysin Inhibitors

Prodrugs

Gastrointestinal Inflammatory Disease

Crohn's Disease

Ulcerative Colitis

Dual-acting Antihypertensive Agents

Benzoimidazole

Oxazole

Pyrazole

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12358931 - 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor (2025-07-15),

2. 12172994 - Pyrimidine compound as JAK kinase inhibitor (2024-12-24),

3. 11897874 - Compounds and methods for modulating Interleukin-2-inducible T-cell kinase (2024-02-13),

4. 11814377 - Pyrimidine compound as JAK kinase inhibitor (2023-11-14),

5. 11780852 - Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (2023-10-10),

6. 11608354 - Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease (2023-03-21),

7. 11420965 - Pyrimidine compound as JAK kinase inhibitor (2022-08-23),

8. 11306099 - Compounds and methods for modulating Bruton's Tyrosine Kinase (2022-04-19),

9. 11110095 - Pyrimidine compounds as JAK kinase inhibitors (2021-09-07),

10. 11008314 - Compounds and methods for modulating interleukin-2-inducible t-cell kinase (2021-05-18),

11. 10988470 - Pyrimidine compound as JAK kinase inhibitor (2021-04-27),

12. 10961267 - Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease (2021-03-30),

13. 10947254 - Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (2021-03-16),

14. 10870652 - Compounds and methods for modulating bruton's tyrosine kinase (2020-12-22),

15. 10774080 - Pyrimidine compound as JAK kinase inhibitor (2020-09-15),

Title: The Innovative Journey of Ryan Hudson

Introduction: Ryan Hudson, a visionary inventor based in San Jose, CA, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Ryan Hudson's latest patents include a cutting-edge virtual reality headset that has revolutionized the gaming industry, as well as a patented smart home automation system that has simplified the way we interact with our living spaces.

Career Highlights: With a background in computer science and engineering, Ryan Hudson has spent over two decades pushing the boundaries of technology. His career highlights include founding a successful tech startup that was later acquired by a major tech conglomerate, as well as receiving multiple awards for his innovative contributions to the field.

Collaborations: Throughout his career, Ryan Hudson has collaborated with leading tech companies, research institutions, and universities to further develop his inventions. His collaborative spirit has led to the creation of groundbreaking technologies that have had a lasting impact on society.

Conclusion: Ryan Hudson's passion for innovation and his relentless drive to push the limits of technology have solidified his place as a pioneering inventor in the tech industry. His dedication to creating cutting-edge solutions continues to inspire the next generation of inventors and innovators.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…